Cyclacel Pharmaceuticals

United States
Berkeley Heights, New Jersey, United States, 07922

Company profile

Cyclacel Pharmaceuticals company profile

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Professor Sir David Lane, a recognized leader in the field of tumor suppressor biology, who discovered the p53 protein, founded the Company in 1996. In 1999, Cyclacel Pharmaceuticals was joined by Professor David Glover, a recognized leader in the mechanism of mitosis or cell division, who discovered, among other cell cycle targets, the mitotic kinases, Polo and Aurora, enzymes that act in the mitosis phase of the cell cycle.

Business identity

Contact email
[email protected]
Phone number
+1 (908) 517 7330
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0+
Founded
1996-01-01, Year

Headquarters

Postal code
07922
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
16
Total equity funding
$202.1M
Last funding
Post IPO Equity / $3M / 2025-06-20
Last equity funding
Post IPO Equity / $3M
Investors
14
Lead investors
2
Founders
1
Articles
125
Exited on
2006-03-28

Founders and investors

Founders

David Lane

Lead investors

Excalibur Fund ManagersScottish Equity Partners

Investors

DC ThomsonHBM PartnersScottish Equity PartnersTemasek HoldingsUOB Venture